Imugene Limited (IMU.AX)

0.0490 +0.0010 (+2.08%) At close: 04:10PM AEDT

Imugene Limited

4-6 Bligh Street
Suite 12.01, Level 12
Sydney, NSW 2000
Australia
61 2 9423 0881
https://www.imugene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Executive Chairman	322.69k	N/A	1956
Ms. Leslie Chong	CEO, MD & Executive Director	1.39M	N/A	N/A
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD	CFO & Company Secretary	521.65k	N/A	1967
Dr. Bradley Glover M.B.A., Ph.D.	Chief Operating Officer	876.97k	N/A	1969
Dr. Joseph Paul Woodard Jr., M.D.	Chief Medical Officer	1M	N/A	N/A
Ms. Ursula McCurry	Chief Clinical Operations Officer	N/A	N/A	N/A
Dr. John Byon	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Corporate governance

Imugene Limited’s ISS governance QualityScore as of 1 October 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.